Introduction
============

Williams-Beuren syndrome (WBS) is a rare disease with an estimated incidence of 1 in 7,500-10,000 persons[@B1][@B2] that is caused by a hemizygous microdeletion of chromosome 7q11.23. The chromosome 7q11.23 region contains 26 to 28 genes[@B2][@B3], including the *ELN*, gene which is known to contribute to the phenotype[@B4]. Several other genes in the WBS critical region are known to be implicated in its phenotype[@B5]. The *FZD9*, *BAZ1B*, and *STX1A* genes in mouse models are known to cause osteopenia, hypercalcemia, and impaired glucose tolerance, respectively[@B4]. WBS is mostly diagnosed by fluorescent *in situ* hybridization (FISH) using an *ELN* specific probe that demonstrates deletion of *ELN*[@B4][@B6]. Other diagnostic methods include multiplex ligation dependent-probe amplification analysis, microsatellite marker analysis, and quantitative polymerase chain reaction analysis[@B4].

Common clinical features of this syndrome include dysmorphic facial features, global cognitive impairment, supravalvular aortic stenosis, and renal and urinary tract abnormalities[@B3]. Endocrine abnormalities such as short stature, precocious puberty, hypothyroidism, and hypercalcemia accompany this syndrome[@B6][@B7][@B8]. Short stature, early puberty, subclinical hypothyroidism, overt hypothyroidism and hypercalcemia have been reported in 30% to 40%, 50%, 2%, 15%, and 5% to 15% of patients, respectively[@B4][@B6][@B9]. The pathophysiology and outcomes of endocrine symptoms remain to be elucidated and treatment is focused on relieving symptoms and preventing complications. This study was performed to investigate the frequency, clinical characteristics, and outcomes of endocrine manifestations in patients with WBS.

Materials and methods
=====================

1. Subjects
-----------

This study included 102 consecutive patients (64 males \[62.7%\] and 38 females \[37.3%\]) with WBS diagnosed between May 1993 and July 2015 in Asan Medical Center. The most common presenting sign was developmental delay (47.6%), followed by cardiac anomaly such as supravalvular aortic stenosis and mitral valve prolapse (31.1%), facial dysmorphism (5.8%), and failure to thrive (1.9%). FISH was performed in patients with clinical features of WBS such as typical facial dysmorphism, developmental delay, cardiac anomaly, and hypercalcemia. Deletion of the 7q11.23 region was identified by FISH in 102 patients ([Fig. 1](#F1){ref-type="fig"}).

2. Endocrine characteristics
----------------------------

Auxological parameters such as height, weight, and body mass index (BMI) were analyzed retrospectively. Each parameter was expressed as a standard deviation score (SDS) according to the normative data from Korean reference sources[@B10]. Patients with short stature were defined as being of height below the third percentile and final adult height was reviewed among patients older than 18 years. Serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-binding protein-3 (IGFBP-3) levels were measured by immunoradiometric assay (Immunotech, Marseille, France) and expressed as *z*-scores calculated based on normative data from Korean reference sources[@B11]. Bone age was determined using the Greulich-Pyle method[@B12].

Luteinizing hormone, follicle stimulating hormone, testosterone (males), or estradiol (females) levels were measured in patients with precocious puberty. Central precocious puberty was defined as the onset of breast development before the age of 8 years in girls and by the onset of testicular development (volume ≥4 mL) before the age of 9 years in boys[@B13]. Early puberty was defined as the onset of pubertal signs at 8--10 years in girls and 9--11 years in boys[@B13]. Central precocious puberty was diagnosed by a gonadotropin releasing hormone (GnRH) stimulation test using an intravenous bolus of a standard dose of 2.5 µg/kg. Thyroid functions, including free T4 and thyroid stimulating hormone (TSH) levels, were measured in 62 patients. Patients with serum TSH levels higher than 10 µU/mL with normal or low T4 were considered to have hypothyroidism[@B14][@B15]. Patients whose TSH levels were slightly above 10 µU/mL were re-evaluated after 2--4 weeks later and those who had persistently high TSH levels were treated with levothyroxine. Serum calcium and phosphorus levels, nephrocalcinosis on kidney ultrasonography, and treatment methods with duration of treatment were assessed.

Results
=======

1. Growth and puberty
---------------------

The age at diagnosis and last follow-up were 3.7±4.4 years (range, 1 month to 19 years) and 12±6.1 years (range, 25 months to 26 years), respectively. Height-SDS, weight-SDS, and BMISDS at presentation were --1.1±1.1, --1.4±1.4, and --1.4±1.3, respectively. Height-SDS, weight-SDS, and BMI-SDS at last follow-up were --1.0±1.1, --1.0±1.4, and --0.6±1.4, respectively. BMI-SDS increased as the patients grew older (*P*\<0.001).

Short stature was found in 26 patients (28.3%) among those older than 2 years of age. Their height-SDS, weight-SDS, and BMI were --2.38±0.62 (range, --3.97 to --1.6 SDS), --1.74±1.53 (range, --3.95 to 1.8) and 18.2±4.6 kg/m^2^ (range, 13.1--34.5 kg/m^2^), respectively. Birth weight was 2.7±0.5 kg (range, 1.9--3.7 kg) in 15 patients whose birth weight data was available; 8 of them were small for gestational age. Five females and 1 male reached final adult height; the mean height of these females was 148.6±5.8 cm (--2.56±1.27 SDS) and that of 1 male was 167.8 cm (--0.97 SDS). Serum IGF-1 and IGFBP-3 levels were measured in 8 patients; IGF-1- and IGFBP-3-SDS were 0.82±1.82 (range, --1.39 to 4.03) and --0.37±1.56 (range, --1.53 to 3.05), respectively.

Two males and 1 female (3 of 102, 2.9%) were diagnosed with central precocious puberty and 2 males and 2 females displayed early puberty (4 of 102, 3.9%) but did not meet the criteria for central precocious puberty ([Table 1](#T1){ref-type="table"}). The 2 males with central precocious puberty were 8.8 years and 8.9 years old when they presented with testicular enlargement. The female patient with central precocious puberty presented with breast enlargement at the age of 7.4 years. The difference between bone age and chronological age (BA--CA) of the three patients with central precocious puberty was 1.8±0.5 years (range, 1.3--2.3 years). One of the male\'s predicted adult height (PAH) and midparental height were 159.1 cm and 168 cm, respectively. He was treated with a GnRH agonist for 28 months and grew from 135.7 cm (--0.21 SDS) at age 9.9 years to 145.6 cm (--0.64 SDS) at age 12.3 years, with a PAH of 162.7 cm. The other male patient was lost to follow-up. The female patient with a PAH of 153.1 cm and midparental height of 162 cm was administered a GnRH agonist for 3 years and grew from 127.6 cm (0.34 SDS) at age 8.1 years to 153 cm (--0.4 SDS) at the age of 11.1 years. Menarche occurred at the age of 12.1 years.

2. Thyroid dysfunction
----------------------

Nine patients (8.8%) were diagnosed with primary hypothyroidism at age 4.0±4.3 years (range, 1 month to 12.1 years); their serum TSH and free T4 levels were 15.2±5.4 µU/mL and 1.2±0.2 ng/dL, respectively ([Table 2](#T2){ref-type="table"}). Levothyroxine treatment was discontinued in 5 patients after normalization of thyroid hormone level and their treatment duration was 34±22.4 months (range, 9--70 months). Two patients with congenital hypothyroidism are still under treatment with levothyroxine at the current ages of 3 and 8 years. Two patients were not followed up. Thyroid autoantibody tests were negative in all patients. Thyroid ultrasonography was performed in 2 patients, and both of them showed thyroid hypoplasia.

3. Hypercalcemia
----------------

The serum calcium level was measured before 3 years of age among 55 patients, with a serum calcium level of 10.6±1.7 mg/dL (range, 8.6--16.5 mg/dL). Hypercalcemia was observed in 12 patients (12 of 55, 22%) at the age of 14.3±6.6 months (range, 7--28 months), with a serum calcium level of 13.1±2.1 mg/dL (range, 11--16.5 mg/dL) ([Table 3](#T3){ref-type="table"}). Half of them required treatment to reduce their serum calcium level; intravenous hydration and diuretics were administered to 6 patients and all but 1 patient improved within several days to weeks. The other 6 patients showed spontaneous resolution of hypercalcemia. Parathyroid hormone levels were suppressed in all but 1 patient. Renal ultrasonography was performed in five patients and all of them displayed nephrocalcinosis.

Discussion
==========

This study demonstrated that endocrine dysfunctions such as short stature, precocious puberty, hypothyroidism, and hypercalcemia are relatively common in patients with WBS. Short stature and central precocious puberty were found in 28.3% and 2.9% of children, respectively. Thyroid dysfunction was diagnosed in 8.8% and it was managed with levothyroxine. Hypercalcemia was found in 22% of patients under the age of 3 years.

Short stature is not evident at birth, but it manifests in early childhood[@B16][@B17]. Short stature was reported in 33% at preschool age and 67% at school age in a previous Korean study[@B18]. However, about 50% to 60% of patients with WBS reach a final adult height below their target height range[@B8][@B19]. Short stature is caused by several factors, such as feeding difficulty, gastroesophageal reflux disease, vomiting, colic, and early puberty[@B4]. Feeding difficulties are reported in 70% to 80% of patients[@B6]. The gastrointestinal symptoms such as colic, diminished appetite, and constipation are also related to hypercalcemia and regular follow-up of serum calcium level is needed[@B4]. The pubertal growth spurt occurs 1 to 2 years earlier and the duration is shorter than normal, which may also contribute to short final adult height[@B19][@B20]. The incidence of early puberty in WBS is reported as high as 50%, but true precious puberty is rare[@B6]. In the present study, only 3 patients (2.9%) were diagnosed with central precocious puberty by a GnRH stimulation test and 2 of them required long term GnRH agonist therapy.

In this study, BMI-SDS was increased as patients grew older. Type 2 diabetes mellitus has been reported in 15% of adult patients with WBS[@B17], but none were diagnosed in this study, probably because the number of adult patients was small.

Among the patients who were diagnosed with primary hypothyroidism, all of them underwent levothyroxine treatment. Careful monitoring of thyroid function is needed to determine the need for supplementation of thyroid hormone[@B21]. The prevalence of subclinical hypothyroidism is known to be inversely related to age[@B22]. Patients with congenital hypothyroidism are rare, but it could be the initial presentation leading to early diagnosis[@B23]. Immaturity of the hypothalamicpituitary-thyroid axis was suggested to be the cause, but the molecular mechanism of hypothyroidism in WBS remains uncertain[@B24]. In this study, 2 patients who underwent thyroid imaging showed hypoplasia of the thyroid gland. Up to 70% of patients with hypothyroidism showed morphological or volumetric abnormalities such as thyroid hypoplasia, therefore, thyroid imaging is recommended in all patients with WBS[@B23][@B24]. However, as in this study, autoimmune thyroiditis is rarely observed.

Symptomatic hypercalcemia in WBS is rare, but careful monitoring and appropriate management is required in the case of severe hypercalcemia. There are some reports of rebound hypercalcemia after treatment, emphasizing the importance of re-evaluating serum calcium levels during the follow-up period[@B25][@B26]. The cases in this study were treated with conventional therapies such as intravenous fluid and diuretics. Symptomatic hypercalcemia usually resolves during childhood[@B6]. Intravenous pamidronate could be useful in the case of intractable hypercalcemia by intravenous hydration with furosemide or hydrocortisone[@B26]. The gene causing hypercalcemia in WBS has not been identified yet. Overexpression of *TRPC3* channels, which is known to be related to calcium transport in lymphocytes, was reported in a patient with WBS[@B27]. Increased 1,25-dihydroxyvitamin D3 levels during the hypercalcemic phase was reported in a previous study, suggesting that abnormal synthesis of 1,25-dihydroxyvitamin D3 seems to be the cause of hypercalcemia in WBS[@B28]. Serum 1,25-dihydroxyvitamin D3 levels were not elevated in our cohort, although it was measured in only 3 patients.

In conclusion, patients with WBS manifest various endocrine dysfunctions, such as postnatal growth retardation, central precocious puberty, hypothyroidism, and hypercalcemia. The severity and outcomes of their endocrine manifestations are heterogeneous. Therefore, long-term follow-up and longitudinal study is needed to develop monitoring guidelines for the endocrine problems and the disease-specific growth curve for patients with WBS in Korea.
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![Fluorescent *in situ* hybridization showing deletion of the *ELN* gene at chromosome 7q11.23.](apem-21-15-g001){#F1}

###### Clinical and endocrine characteristics of patients with central precocious puberty

![](apem-21-15-i001)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pt   Sex   Age at diagnosis\   Bone age\   Height-SDS   Weight-SDS   Tanner stage                         LH (basal/peak)\   FSH (basal/peak)\   Testosterone or estradiol   GnRH agonist
             (yr)                (yr)                                                                       (mIU/mL)           (mIU/mL)                                        
  ---- ----- ------------------- ----------- ------------ ------------ ------------------------------------ ------------------ ------------------- --------------------------- ------------------------------------------
  1    M     8                   12          --0.8        --0.45       III (testicle: Rt. 6 mL; Lt. 4 mL)   4.1/14.9           8.0/15              2.6 ng/mL                   Lost to follow up

  2    M     8                   11          0.18         --1.24       II (testicle: both 6 mL)             0.32/14.6          2.0/5.3             2.1 ng/mL                   Triptorelin 2.06 mg for 18 months

  3    F     7                   8           0.31         --0.95       II                                   2.2/8.8            2.9/11.5            17.7 pg/mL                  Leuprolelin acetate 1.875 mg for 3 years
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Pt, patient; SDS, standard deviation score; LH, luteinizing hormone; FSH, follicle-stimulating hormone; GnRH, gonadotropin releasing hormone; Rt, right; Lt, left.

###### Nine patients (8.8%) with primary hypothyroidism

![](apem-21-15-i002)

  Pt   Age at diagnosis (yr)   TSH (µU/mL)    FT4 (ng/dL)   Thyroglobulin (ng/mL)   Thyroid autoantibody   Thyroid imaging   Duration of L-T4 treatment (mo)
  ---- ----------------------- -------------- ------------- ----------------------- ---------------------- ----------------- ---------------------------------
  1    0.1                     21.9           1.0           ND                      Normal                 ND                29
  2    0.9                     12.1           1.2           ND                      ND                     ND                26
  3    12.1                    13.2           1.2           7.8                     Normal                 ND                62
  4    2.3                     18.8           1.5           ND                      Normal                 ND                36^b)^
  5    7.5                     10.1           1.5           ND                      Normal                 ND                9
  6    2.8                     14.8           1.4           ND                      ND                     ND                5^a)^
  7    8.5                     10.4           1.1           ND                      Normal                 Hypoplasia        70
  8    1.3                     11.1           0.92          ND                      ND                     ND                5^a)^
  9    0.1                     24.8           0.82          ND                      Normal                 Hypoplasia        98^b)^
       4.0±4.3^c)^             15.2±5.4^c)^   1.2±0.2^c)^                                                                    

Pt. patient; TSH, thyroid stimulating hormone; ND, not done.

^a)^Patients who were not followed up. ^b)^Patients who have been under treatment. ^c)^Mean±standard deviation.

###### Clinical and endocrine characteristics of patients with hypercalcemia

![](apem-21-15-i003)

  Pt   Age at diagnosis (mo)   PTH (10--60 pg/mL)   Calcium (mg/dL)   25(OH)D3 (8--51.9 ng/mL)   1,25(OH)D3 (19.6--54.3 pg/mL)   Urine Ca/Cr ratio (16.5--144 mg/g)   Nephrocalcinosis   Treatment     Duration of treatment
  ---- ----------------------- -------------------- ----------------- -------------------------- ------------------------------- ------------------------------------ ------------------ ------------- -----------------------
  1    12                      ND                   11.5              ND                         ND                              ND                                   ND                 PD            14 Days
  2    9                       5.7                  11.3              40.6                       21.1                            ND                                   ND                 ND            ND
  3    25                      ND                   12.3              ND                         ND                              ND                                   ND                 ND            ND
  4    8                       ND                   11.0              ND                         ND                              ND                                   ND                 HC            14 Days
  5    7                       ND                   11.3              ND                         ND                              ND                                   ND                 IVH, FS, HC   16 Days
  6    15                      ND                   13.3              ND                         ND                              2008.3                               Yes                HC            9 Months
  7    10                      4.8                  14.5              61.3                       5.9                             1563.6                               Yes                IVH, FS, HC   18 Days
  8    28                      \<3.0                16.5              106                        ND                              ND                                   Yes                IVH, FS       3 Days
  9    19                      12.4                 15.5              ND                         ND                              ND                                   Yes                ND            ND
  10   14                      1.9                  16.5              107                        9.6                             1671.3                               Yes                ND            ND
  11   12                      ND                   11.7              ND                         ND                              39.4                                 ND                 ND            ND
  12   13                      ND                   11.7              ND                         ND                              ND                                   ND                 ND            ND
       14.3±6.6^a)^                                 13.1±2.1^a)^                                                                                                                                       

Pt. patient; PTH, parathyroid hormone; 25(OH)D3, 25-dihydroxyvitamin D3; 1,25(OH)D3, 1,25-dihydroxyvitain D3; Cr, creatinine; PD, prednisolone; HC, hydrocortisone; IVH, intravenous hydration; FS, furosemide; ND, not done.

^a)^Mean±standard deviation.
